Multipotent, dedifferentiated cancer stem-like cells from brain gliomas

Stem Cells and Development

Volumn 15, Issue 3, 2006, Pages 423-435

  Kang, Soo Kyung ^a   Park, Jong Bae ^b   Cha, Seung Heun ^a  

^a Pusan National University School of Medicine   (South Korea)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; COMPLEMENTARY DNA; EPITOPE; NITROSOUREA DERIVATIVE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CANCER; BRAIN TISSUE; CANCER CELL; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MICROARRAY ANALYSIS; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; DNA, COMPLEMENTARY; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES; GLIOMA; HUMANS; MICE; MICE, SCID; MULTIPOTENT STEM CELLS; NEOPLASM METASTASIS; NEURONS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 33746216943     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2006.15.423     Document Type: Article

References (36)

1. Sell S. (2004). Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51:1-28.
2. Brustle O and RD McKay. (1995). The neuroepithelial stem cell concept: implications for neurooncology. J Neurooncol 24:57-59.
3. Holland EC. (2000). A mouse model for glioma: biology, pathology, and therapeutic opportunities. Toxicol Pathol 28:171-177.
4. Holland EC, J Celestino, C Dai, L Schaefer, RE Sawaya and GN Fuller. (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature Genet 25:55-57.
5. Morrison SJ. (2001). Stem cell potential: can anything make anything? Curr Biol 11:R7-R9.
6. Al-Hajj M, MW Becker, M Wicha, I Weissman and MF Clarke. (2004). Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:43-47.
7. Dontu G, D El-Ashry and MS Wicha. (2004). Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15:193-197.
8. Woodruff MF. (1983). Cellular heterogeneity in tumours. Br J Cancer 47:589-594.
9. Sell S and GB Pierce. (1994). Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 70:6-22.
10. Reya T, SJ Morrison, MF Clarke and IL Weissman. (2001). Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
11. Tu SM, SH Lin and CJ Logothetis. (2002). Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3:508-513.
12. Al-Hajj M, MS Wicha, A Benito-Hernandez, SJ Morrison and MF Clarke. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988.
13. Griffin J. (2001). The biology of signal tansduction inhibition: basic science to novel therapies. Semin Oncol 28:3-8.
14. Sawyers CL. (2002). Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev 12:111-115.
15. Kilic T, JA Alberta, PR Zdunek, M Acar, P Iannarelli and T O'Reilly. (2000). Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylamino-pyrimidine class. Cancer Res 60:5143-5150.
16. Druker BJ, CL Sawyers, H Kantarjian, DJ Resta, SF Reese and JM Ford. (2001). Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042.
17. Neshat MS, IK Mellinghoff, C Tran, B Stiles, G Thomas and R Petersen. (2001). Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314-10319.
18. Zhou S, JD Schuetz, KD Bunting, AM Colapietro, J Sampath and JJ Morris. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med 7:1028-1034.
19. Zhou S, JJ Morris, Y Barnes, L Lan, JD Schuetz and BP Sorrentino. (2002). Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99:12339-12344.
20. Gottesman MM, T Fojo and SE Bates. (2002). Multidrug resistance in cancer, role of ATP-dependent transporters. Nature Rev Cancer 2:48-58.
21. Makino S. (1956). Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann NY Acad Sci 63:818-830.
22. Kleinsmith LJ and GB Pierce. (1964). Multipotentiality of single embryonal carcinoma cells. Cancer Res 24:1544-1551.
23. Gale RP and A Butturini. (1992). Leukemia: stem cells, preleukemia and cure. Leukemia 6:80-85.
24. Wulf GG, RY Wang, I Kuehnle, D Weidner, F Marini and MK Brenner. (2001). A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98:1166-1173.
25. Kondo T, T Setoguchi, and T Taga. (2004). Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci. USA. 101:781-786.
26. Mischel PS, R Shai, T Shi, S Horvath, KV Lu and G Choe. (2003). Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22:2361-2373.
27. Jogi A, I Ora, H Nilsson, L Poellinger, H Axelson and S Pahlman. (2003). Hypoxia-induced dedifferentiation in neuroblastoma cells. Cancer Lett 197:145-150.
28. Holland EC, Y Li, J Celestino, C Dai, L Schaefer and RA Sawaya. (2000). Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol 157:1031-1037.
29. Dai C, JC Celestino, Y Okada, DN Louis, GN Fuller and EC Holland. (2001). PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913-1925.
30. Bachoo RM, EA Maher, KL Ligon, NE Sharpless, SS Chan and MJ You. (2002). Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277.
31. Jogi A, J Vallon-Christersson, L Holmquist, H Axelson, A Borg and S Pahlman. (2004). Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res 295:469-487.
32. Vogelstein B and KW Kinzler KW. (2004). Cancer genes and the pathways they control. Nat Med 10:789-799.
33. Golub TR, DK Slonim, P Tamayo, C Huard, M Gaasenbeek and JP Mesirov. (1999). Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286:531-537.
34. Alizadeh AA, MB Eisen, RE Davis, C Ma, IS Lossos, AJ Rosenwald and C Boldrick. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
35. Perou CM, T Sorlie, MB Eisen, M van de Rijn, SS Jeffrey and CA Rees. (2000). Molecular portraits of human breast tumours. Nature 406:747-752.
36. MacDonald TJ, KM Brown, B LaFleur, K Peterson, C Lawlor and Y Chen. (2001). Expression profiling of medulloblastoma: PDGFRA and RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29: 143-152.